English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The use of beta-blockers should be avoided in the treatment of patients with asthma and COPD because of their broncho-constrictive effect if there are medical alternatives available. This is the case in arterial hypertension, glaucoma, supraventricular and ventricular dysrhythmia. The use of beta-I-selective drugs is indicated in the treatment of patients with coronary heart disease after myocardial infarction, since the benefit of reduction of morbidity and mortality through the coronary heart disease outweighs the potential risks if the patient is under close and careful observation and the initial dose of the beta-blocker is low. On principle patients suffering from asthma bronchiale should not be treated with beta-blockers because the risk of severe airway obstruction is higher than in patients with COPD.

Beta-Rezeptorenblocker bei Patienten mit obstruktiven Atemwegserkrankungen - Risiken und Alternativen